180 related articles for article (PubMed ID: 29187463)
21. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
22. Primary splenic lymphoma.
Aslam M; Salamat N; Mamoon N; Ahmed M
J Coll Physicians Surg Pak; 2006 Apr; 16(4):307-8. PubMed ID: 16624203
[TBL] [Abstract][Full Text] [Related]
23. Women with Diffuse Large B Cell Lymphoma Benefit More from Rituximab-Containing Chemotherapy.
Huang HH; Hsiao FY; Chen LJ; Chen HM; Ko BS
J Womens Health (Larchmt); 2019 Feb; 28(2):203-211. PubMed ID: 29924676
[TBL] [Abstract][Full Text] [Related]
24. Rituximab maintenance therapy for patients with diffuse large B-cell lymphoma: A meta-analysis.
Zhou X; Ma T; Zhang Y; Zhou N; Li J
PLoS One; 2017; 12(3):e0174648. PubMed ID: 28355276
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study.
Zheng W; Liu M; Guan L; Wang S
Cancer Med; 2024 Apr; 13(8):e7120. PubMed ID: 38629251
[TBL] [Abstract][Full Text] [Related]
26. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
[TBL] [Abstract][Full Text] [Related]
27. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M; Schechter GP
Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
[TBL] [Abstract][Full Text] [Related]
28. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
[TBL] [Abstract][Full Text] [Related]
29. Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?
Epperla N; Vaughn JL; Othus M; Hallack A; Costa LJ
Cancer Med; 2020 Aug; 9(15):5519-5525. PubMed ID: 32558356
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
31. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.
Kalpadakis C; Pangalis GA; Angelopoulou MK; Sachanas S; Kontopidou FN; Yiakoumis X; Kokoris SI; Dimitriadou EM; Dimopoulou MN; Moschogiannis M; Korkolopoulou P; Kyrtsonis MC; Siakantaris MP; Papadaki T; Tsaftaridis P; Plata E; Papadaki HE; Vassilakopoulos TP
Oncologist; 2013; 18(2):190-7. PubMed ID: 23345547
[TBL] [Abstract][Full Text] [Related]
32. Role of Radiation Therapy in Younger and Older Adults with Primary Mediastinal Large B Cell Lymphoma in Rituximab Era: A U.S. Population-Based Analysis.
Jiang S; Zhen H; Jiang H
J Adolesc Young Adult Oncol; 2019 Oct; 8(5):623-627. PubMed ID: 31150309
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
34. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
35. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
36. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
[No Abstract] [Full Text] [Related]
37. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
[TBL] [Abstract][Full Text] [Related]
38. Risk-tailored treatment of splenic marginal zone lymphoma.
Castelli R; Balzarotti M; Salvi E; Simona Rossi R; Lambertenghi Deliliers G; Bergamaschini L; Gidaro A
Anticancer Drugs; 2022 Jan; 33(1):e36-e42. PubMed ID: 34407041
[TBL] [Abstract][Full Text] [Related]
39. Features and outcomes of diffuse large B-cell lymphoma of the thyroid in a large contemporary cohort.
Costa LJ; Xavier AC
Leuk Lymphoma; 2014 Feb; 55(2):283-7. PubMed ID: 23647064
[TBL] [Abstract][Full Text] [Related]
40. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
